Design, synthesis, and interaction study of quinazoline-2(1 H)-thione derivatives as novel potential Bcl-xL inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 9, 2010, Pages 3465-3479

  Feng, Yu ^a   Ding, Xiao ^a   Chen, Tao ^b   Chen, Lili ^a   Liu, Fang ^c   Jia, Xu ^a   Luo, Xiaomin ^a   Shen, Xu ^a   Chen, Kaixian ^a   Jiang, Hualiang ^a   Wang, Hui ^b   Liu, Hong ^a   Liu, Dongxiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [[7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]ETHYL]PHENOXY]ACETIC ACID; 2 [3 [(9 OXO 7 PHENYL) 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [3 [[5 (2 METHOXYPHENYL) 3 OXO 7 PHENYL 3,5 DIHYDRO 2H THIAZOLO[3,2 A]PYRIMIDIN 2 YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [3 [[7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B] QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [3 [[7 (3 FLUOROPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [3 [[7 (FURAN 2 YL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [3 [[7 (NAPHTHALEN 1 YL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 [4 [[7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B] QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]ACETIC ACID; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 3 [4 [[(7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDINE]METHYL]PHENYL]ACRYLIC ACID; 3 [5 [(9 OXO 7 PHENYL 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE)METHYL]FURAN 2 YL]BENZOIC ACID; 3 [5 [[ 7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]FURAN 2 YL]BENZOIC ACID; 3 [[2 METHOXY 4 [[7 (4 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]PHENOXY]METHYL]BENZOIC ACID; 3' [[7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]BIPHENYL 3 CARBOXYLIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [[7 (2 METHOXYPHENYL) 9 OXO 5H BENZO[H]THIAZOLO[2,3 B]QUINAZOLIN 10(6H,7H,9H) YLIDENE]METHYL]BENZOIC ACID; ANTINEOPLASTIC AGENT; BH 3I 1; BH 3I 2; CASPASE; DCBL 55; GOSSYPOL; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; QUINAZOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CYTOTOXICITY; DATA BASE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; INTRAHEPATIC BILE DUCT; LEUKEMIA; MITOCHONDRIAL MEMBRANE; MOLECULAR DOCKING; MOLECULAR MODEL; MUTAGENESIS; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; SCREENING; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MITOCHONDRIAL MEMBRANES; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952043774     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901004c     Document Type: Article

References (26)

1. Kerr, J. F.; Winterford, C. M.; Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy Cancer 1994, 73, 2013-2026
2. Del Principe, M. I.; Del Poeta, G.; Venditti, A.; Buccisano, F.; Maurillo, L.; Mazzone, C.; Bruno, A.; Neri, B.; Irno Consalvo, M.; Lo Coco, F.; Amadori, S. Apoptosis and immaturity in acute myeloid leukemia Hematology 2005, 10, 25-34
3. L-Bak peptide complex: recognition between regulators of apoptosis Science 1997, 275, 983-986
4. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7124-7129
5. L) Nat. Cell Biol. 2001, 3, 173-182
6. Reed, J. C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies Blood 2005, 106, 408-418
7. Zhai, D.; JC.; Satterthwait, A. C.; Reed, J. C. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins Cell Death Differ. 2006, 13, 1419-1421
8. O'Brien, S.; Kipps, T. J.; Faderl, S.; Crump, M.; Keating, M. J.; Anderson, B.; Soho, C.; Bole, J.; Turner, R.; Viallet, J.; Cheson, B. D. A phase I trial of the small molecule pan-bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL) Blood 2005, 106, 135A-135A
9. Flack, M. R.; Pyle, R. G.; Mullen, N. M.; Lorenzo, B.; Wu, Y. W.; Knazek, R. A.; Nisula, B. C.; Reidenberg, M. M. Oral gossypol in the treatment of metastatic adrenal cancer J. Clin. Endocrinol. Metab. 1993, 76, 1019-1024
10. EpsteA. L.; Levy, R.; Kim, H.; Henle, W.; Henle, G.; Kaplan, H. S. Biology of human malignant-lymphomas. 4. Functional characterization of 10 diffuse histiocytic lymphoma cell lines Cancer 1978, 42, 2379-2391
11. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B. L.; Wendt, M. D.; Zhang, H. C.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
12. Green, R. J.; Frazier, R. A.; Shakesheff, K. M.; Davies, M. C.; Roberts, C. J.; Tendler, S. J. Surface plasmon resonance analysis of dynamic biological interactions with biomaterials Biomaterials 2000, 21, 1823-1835
13. Trudel, S.; Li, Z. H.; Rauw, J.; Tiedemann, R. E.; Wen, X. Y.; Stewart, A. K. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma Blood 2007, 109, 5430-5438
14. Vogler, M.; Weber, K.; Dinsdale, D.; Schmitz, I.; Schulze-Osthoff, K.; Dyer, M. J.; Cohen, G. M. Different forms of cell death induced by putative Bcl-2 inhibitors Cell Death Differ. 2009, 16, 1030-1039
15. Zamzami, N.; Marchetti, P.; Castedo, M.; ZanC.; Vayssiere, J. L.; Petit, P. X.; Kroemer, G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo J. Exp. Med. 1995, 181, 1661-1672
16. Smiley, S. T.; Reers, M.; Mottola-Hartshorn, C.; LM.; Chen, A.; Smith, T. W.; Steele, G. D., Jr.; Chen, L. B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1 Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3671-3675
17. Mohammad, R. M.; GoustA. S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 Clin. Cancer Res. 2007, 13, 2226-2235
18. Zhang, M.; Ling, Y.; Yang, C. Y.; Liu, H.; Wang, R.; Wu, X.; Ding, K.; Zhu, F.; Griffith, B. N.; Mohammad, R. M.; Wang, S.; Yang, D. A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3- oxide (MNB)-induced apoptosis in leukemia cells Ann. Hematol. 2007, 86, 471-481
19. Rothe, G.; Valet, G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′- dichlorofluorescin J. Leukocyte Biol. 1990, 47, 440-448
20. An, J.; Chen, Y.; Huang, Z. Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor J. Biol. Chem. 2004, 279, 19133-19140
21. Tsujimoto, Y.; Cossman, J.; Jaffe, E.; Croce, C. M. Involvement of the bcl-2 gene in human follicular lymphoma Science 1985, 228, 1440-1443
22. L can confer a multidrug resistance phenotype Blood 1995, 86, 1903-1910
23. Perego, P.; Righetti, S. C.; Supino, R.; Delia, D.; Caserini, C.; Carenini, N.; Bedogne, B.; Broome, E.; Krajewski, S.; Reed, J. C.; Zunino, F. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines Apoptosis 1997, 2, 540-548
24. Yoshino, T.; Shiina, H.; Urakami, S.; Kikuno, N.; Yoneda, T.; Shigeno, K.; Igawa, M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy Clin. Cancer Res. 2006, 12, 6116-6124
25. Reed, J. C. Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood 2008, 111, 3322-3330
26. L forms two distinct homodimers at non-ionic detergents: implications in the dimerization of Bcl-2 family proteins J. Biochem. 2008, 143, 243-252